Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

User menu

  • My Alerts
  • Log in

Search

  • Advanced search
Neurology Neuroimmunology & Neuroinflammation
Home
A peer-reviewed clinical and translational neurology open access journal
  • My Alerts
  • Log in
Site Logo
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

Share

March 2021; 8 (2) ArticleOpen Access

Altered CSF Albumin Quotient Links Peripheral Inflammation and Brain Damage in MS

Marco Puthenparampil, Paula Tomas-Ojer, Thorsten Hornemann, Andreas Lutterotti, Ilijas Jelcic, Mario Ziegler, Andreas J. Hülsmeier, Carolina Cruciani, Wolfgang Faigle, Roland Martin, Mireia Sospedra
First published March 1, 2021, DOI: https://doi.org/10.1212/NXI.0000000000000951
Marco Puthenparampil
From Neuroimmunology and MS Research (nims) (M.P., P.T.-O., A.L., I.J., M.Z., C.C., W.F., R.M., M.S.), Department of Neurology, University Hospital and University Zurich, Switzerland; Department of Neuroscience DNS (M.P.), University Hospital of Padova, Italy; and Institute for Clinical Chemistry (T.H., A.H.), University Hospital and University Zurich, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: marco_puthen@hotmail.it
Paula Tomas-Ojer
From Neuroimmunology and MS Research (nims) (M.P., P.T.-O., A.L., I.J., M.Z., C.C., W.F., R.M., M.S.), Department of Neurology, University Hospital and University Zurich, Switzerland; Department of Neuroscience DNS (M.P.), University Hospital of Padova, Italy; and Institute for Clinical Chemistry (T.H., A.H.), University Hospital and University Zurich, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: paulatomasojer@gmail.com
Thorsten Hornemann
From Neuroimmunology and MS Research (nims) (M.P., P.T.-O., A.L., I.J., M.Z., C.C., W.F., R.M., M.S.), Department of Neurology, University Hospital and University Zurich, Switzerland; Department of Neuroscience DNS (M.P.), University Hospital of Padova, Italy; and Institute for Clinical Chemistry (T.H., A.H.), University Hospital and University Zurich, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: thorsten.hornemann@usz.ch
Andreas Lutterotti
From Neuroimmunology and MS Research (nims) (M.P., P.T.-O., A.L., I.J., M.Z., C.C., W.F., R.M., M.S.), Department of Neurology, University Hospital and University Zurich, Switzerland; Department of Neuroscience DNS (M.P.), University Hospital of Padova, Italy; and Institute for Clinical Chemistry (T.H., A.H.), University Hospital and University Zurich, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: andreas.lutterotti@usz.ch
Ilijas Jelcic
From Neuroimmunology and MS Research (nims) (M.P., P.T.-O., A.L., I.J., M.Z., C.C., W.F., R.M., M.S.), Department of Neurology, University Hospital and University Zurich, Switzerland; Department of Neuroscience DNS (M.P.), University Hospital of Padova, Italy; and Institute for Clinical Chemistry (T.H., A.H.), University Hospital and University Zurich, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ilijas.jelcic@usz.ch
Mario Ziegler
From Neuroimmunology and MS Research (nims) (M.P., P.T.-O., A.L., I.J., M.Z., C.C., W.F., R.M., M.S.), Department of Neurology, University Hospital and University Zurich, Switzerland; Department of Neuroscience DNS (M.P.), University Hospital of Padova, Italy; and Institute for Clinical Chemistry (T.H., A.H.), University Hospital and University Zurich, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mario.ziegler@usz.ch
Andreas J. Hülsmeier
From Neuroimmunology and MS Research (nims) (M.P., P.T.-O., A.L., I.J., M.Z., C.C., W.F., R.M., M.S.), Department of Neurology, University Hospital and University Zurich, Switzerland; Department of Neuroscience DNS (M.P.), University Hospital of Padova, Italy; and Institute for Clinical Chemistry (T.H., A.H.), University Hospital and University Zurich, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carolina Cruciani
From Neuroimmunology and MS Research (nims) (M.P., P.T.-O., A.L., I.J., M.Z., C.C., W.F., R.M., M.S.), Department of Neurology, University Hospital and University Zurich, Switzerland; Department of Neuroscience DNS (M.P.), University Hospital of Padova, Italy; and Institute for Clinical Chemistry (T.H., A.H.), University Hospital and University Zurich, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: carolina.cruciani@usz.ch
Wolfgang Faigle
From Neuroimmunology and MS Research (nims) (M.P., P.T.-O., A.L., I.J., M.Z., C.C., W.F., R.M., M.S.), Department of Neurology, University Hospital and University Zurich, Switzerland; Department of Neuroscience DNS (M.P.), University Hospital of Padova, Italy; and Institute for Clinical Chemistry (T.H., A.H.), University Hospital and University Zurich, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: wolfgang.faigle@usz.ch
Roland Martin
From Neuroimmunology and MS Research (nims) (M.P., P.T.-O., A.L., I.J., M.Z., C.C., W.F., R.M., M.S.), Department of Neurology, University Hospital and University Zurich, Switzerland; Department of Neuroscience DNS (M.P.), University Hospital of Padova, Italy; and Institute for Clinical Chemistry (T.H., A.H.), University Hospital and University Zurich, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: roland.martin@usz.ch
Mireia Sospedra
From Neuroimmunology and MS Research (nims) (M.P., P.T.-O., A.L., I.J., M.Z., C.C., W.F., R.M., M.S.), Department of Neurology, University Hospital and University Zurich, Switzerland; Department of Neuroscience DNS (M.P.), University Hospital of Padova, Italy; and Institute for Clinical Chemistry (T.H., A.H.), University Hospital and University Zurich, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Altered CSF Albumin Quotient Links Peripheral Inflammation and Brain Damage in MS
Marco Puthenparampil, Paula Tomas-Ojer, Thorsten Hornemann, Andreas Lutterotti, Ilijas Jelcic, Mario Ziegler, Andreas J. Hülsmeier, Carolina Cruciani, Wolfgang Faigle, Roland Martin, Mireia Sospedra
Neurol Neuroimmunol Neuroinflamm Mar 2021, 8 (2) e951; DOI: 10.1212/NXI.0000000000000951

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
804

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1 Characterization of CSF From Patients With MS With and Without Increased QAlb

    (A) Graph shows QAlb minus QNorm. Patients in which this difference is positive are showed in red and those in which is negative in black. Comparison between patients with and without increased QAlb of: (B) quotients and Igs(loc) expressed as percentage (%) for IgA, IgG, and IgM and (C) CSF-infiltrating cells (number of cells/μL) and frequency (%) of lymphocytes and monocytes analyzed under the microscope. (D) Correlation between number of CSF-infiltrating cells and IgG(loc) expressed as percentage (%). Graphs (A–D) represent the main cohort of 121 patients with MS. Each dot in the graphs corresponds to 1 patient, and bars show the mean. A t test for normally distributed variables and U test (Mann-Whitney) for non-normally distributed variables was used to compared patients. Linear correlation was tested using Pearson for normally distributed and Spearman r for non-normally distributed variables. Statistical significance (* p < 0.05, ** p < 0.01, and **** p < 0.0001) is shown. Ig = immunoglobulin; QAlb = serum albumin quotient; QNorm = normal QAlb.

  • Figure 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2 Characterization of CSF-Infiltrating Cells and Markers of CNS Damage in Patients With MS With and Without Increased QAlb

    (A) Comparison between patients with and without increased QAlb of frequencies of Th2-A (CCR6- CCR4+ CRTH2−) in CM CD28+ CD27-, EM CD28+ CD27-, EM CD28-, and TEMRA CD28+ CD27+ CD4+ CSF-infiltrating T cells. (B) Comparison between patients with IgG(loc) (>10%) and without IgG(loc) (<10%) of frequencies of EM CD28+ CD27- CD4+ CSF-infiltrating cells with a Th2-A (CCR6- CCR4+ CRTH2−) functional phenotype. Correlation between these frequencies and IgG(loc) expressed as %. (C) Comparison between patients with and without increased QAlb of frequencies of Th1 (CCR6- CCR4- CRTH2−) cells in EM CD28- CD4+ CSF-infiltrating T cells and amount of IFNγ expressed as pg/mL present in the CSF of 30 patients as well as correlation between the amount of IFNγ and QAlb. (D) Comparison of NF-L and CHI3L1 intrathecal concentration between patients with and without increased QAlb. (E) Correlation between the intrathecal concentration of these 2 biomarkers and QAlb and also between themselves. Graphs (A–C) represent subcohort 1 of 79 patients with MS, and frequencies have been obtained by ex vivo immunophenotyping, and (E–D) represent the main cohort of 121 patients with MS. Each dot in the graphs corresponds to 1 patient, and bars show the mean. Patients with increased QAlb are shown in red. T test t test for normally distributed variables and U test (Mann-Whitney) for non-normally distributed variables was used to compared patients. Linear correlation was tested using Pearson for normally distributed and Spearman r for non-normally distributed variables. Statistical significance (*p < 0.05, **p < 0.01) is shown.

  • Figure 3
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3 Lipidomic Profile in Patients With MS With and Without Increased QAlb

    (A) Heat map of the 10 statistically most significant altered lipid species between patients with MS with and without increased QAlb. The abundance of the lipid species is qualitatively represented by color intensity for each of the 36 patients with MS (subcohort 2). Mean, SD, and p values of the group comparisons are shown. (B) Correlations between QAlb and the intrathecal concentration for 6 of the identified lipid species. Linear correlation between variables was tested using Pearson correlation, and p values are shown. (C) Ratios between mean CSF concentration of lipid species in patients with MS and the concentration in plasma from a reference control cohort with 24 healthy controls. Marked in red are the 4 SM and 5 PC species that were significantly more abundant in patients with MS with increased QAlb. Ig = immunoglobulin; QAlb = serum albumin quotient.

  • Figure 4
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4 Immunophenotyping of Peripheral Circulating Lymphocytes in Patients With MS With and Without Increased QAlb

    Comparison, between patients with (red) and without (black) increased QAlb, of number of CD8+ CM CD28+ Th1 (CCR6- CCR4- CRTH2-) and Th1* (CCR6+ CCR4- CRTH2-), CD4+ CM CD28+ CD27+ Th1 (CCR6- CCR4- CRTH2-) and Th1* (CCR6+ CCR4- CRTH2-), CD4+ EM CD28+ CD27+ Th1 (CCR6- CCR4- CRTH2-) and Th1* (CCR6+ CCR4- CRTH2-), and CD4+ TEMRA CD28+ Th1 (CCR6- CCR4- CRTH2-) and Th1* (CCR6+ CCR4- CRTH2-) in patients with and without increased QAlb, as well as the correlation between these cell counts and QAlb. All graphs represent subcohort 1 consisting of 79 patients with MS. Each dot in the graph corresponds to a single patient, and bars show the mean. T test t test for normally distributed variables and U test (Mann-Whitney) for non-normally distributed variables was used to compared patients. Linear correlation was tested using Pearson for normally distributed and Spearman r for non-normally distributed variables. Statistical significance (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001) is shown. Statistical significance (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001) is shown. QAlb = serum albumin quotient.

  • Figure 5
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5 QAlb Analysis Over Time

    (A and B) Linear representations of QAlb minus QNorm values (B) and number of CSF-infiltrating cells per μL (C) over time in a cohort of 33 patients with MS from which CSF samples at different time points were available. X-axis represents time in months, and Y-axis represents QAlb-QNorm and number of CSF-infiltrating cells per μL. The number of patients in each graph is indicated. The dotted line represents the limit for normal values (0 for QAlb-QNorm and 4 for number of CSF-infiltrating cells). Patients who maintain high levels over time are shown in red, those who maintain low levels in black, and those who change the levels in gray. Fine lines and circles correspond to untreated patients. Patients treated between lumbar punctures are shown with bold lines and squares (dimethyl fumarate), triangles (natalizumab), and diamonds (fingolimod). QAlb = serum albumin quotient; QNorm = normal QAlb.

  • Figure 6
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6 Characterization of CSF-infiltrating Cells in Controls With and Without Increased QAlb

    (A and B) QAlb minus QNorm has been used like in patients with MS to differentiate controls with (in red) and without (in black) increased QAlb. Comparison between controls (ONIND [n = 40] (A) and OIND [n = 21] (B)) with and without increased QAlb of IgA and IgG quotient, CSF-infiltrating cells, and frequency of TH2-A (CCR6- CCR4+ CRTH2-) and TH2-B (CCR6- CCR4+ CRTH2+) in CD4+ CM CD28+ CD27- and in CD4+ EM CD28+ CD27- CSF-infiltrating cells. In all graphs, each dot corresponds to 1 patient, and bars show the mean. T test t test for normally distributed variables and U test (Mann-Whitney) for non-normally distributed variables was used to compared patients. Statistical significance (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001) is shown. Statistical significance (*p < 0.05, **p < 0.01, and ****p < 0.0001) is shown. QAlb = serum albumin quotient; QNorm = normal QAlb.

  • Figure 7
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 7 Characterization of Peripheral Circulating Cells in Controls With and Without Increased QAlb

    (A and B) Comparison between controls (ONIND [n = 40] (A) and OIND (n = 21) (B)) with and without increased QAlb of number of: CD8+ CM CD28+ Th1 (CCR6- CCR4- CRTH2-) and Th1* (CCR6+ CCR4- CRTH2-), CD4+ CM CD28+ CD27+ Th1 (CCR6- CCR4- CRTH2-) and Th1* (CCR6+ CCR4- CRTH2-), CD4+ EM CD28+ CD27+ Th1 (CCR6- CCR4- CRTH2-) and Th1* (CCR6+ CCR4- CRTH2-), and CD4+ TEMRA CD28+ Th1 (CCR6- CCR4- CRTH2-) and Th1* (CCR6+ CCR4- CRTH2-) circulating cells. Cell counts have been determined using SPHEROTM AccuCount Particles. In all graphs, each dot corresponds to 1 patient, and bars show the mean. T test t test for normally distributed variables and U test (Mann-Whitney) for non-normally distributed variables was used to compared patients.

Tables

  • Figures
  • Table 1
  • Table2
  • links.lww.com/NXI/A413

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Glossary
    • Methods
    • Results
    • Discussion
    • Study Funding
    • Disclosure
    • Appendix Authors
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

Preferences and User Experiences of Wearable Devices in Epilepsy A Systematic Review and Mixed-Methods Synthesis

Dr. Daniel Friedman and Dr. Sharon Chiang

► Watch

Related Articles

  • No related articles found.

Topics Discussed

  • Multiple sclerosis
  • Autoimmune diseases

Alert Me

  • Alert me when eletters are published
Neurology - Neuroimmunology Neuroinflammation: 10 (2)

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Neuroimmunology & Neuroinflammation
Online ISSN: 2332-7812

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise